Clinical Trials

370 enrolled

Phase 2 Active not recruiting

Lymphoma, Melanoma

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT07302347 2026-03-03

MK-3475-G21

20 enrolled

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

5 enrolled 11 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

22 enrolled 20 charts

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT03990961 2026-02-20

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

5 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Phase 1 Recruiting

15 enrolled

Phase 2 Active not recruiting

Lymphoma

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 2 FDA

Phase EARLY_PHASE1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

22 enrolled

Lymphoma, Neoplasms, Recurrence

NCT04752826 2026-02-18

MK-3475-D20

DermatologicGynecologicLymphoid

176 enrolled

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT02362997 2026-02-12

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Phase 2 Suspended

18 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT06484920 2026-02-10

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

24 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03598608 2026-02-05

MK-4280-003

Phase 1/2 Completed

137 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

84 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

15 enrolled 9 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06242834 2026-01-14

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

32 enrolled

Lymphoma, B-Cell

NCT03210662 2026-01-13

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

17 enrolled 9 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT03829254 2026-01-12

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

135 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Melanoma

NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

39 enrolled

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT05956041 2026-01-07

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

23 enrolled

Lymphoma, T-Cell, Cutaneous

NCT05179603 2025-12-24

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

14 enrolled 15 charts

Lymphoma, Large B-Cell, Diffuse

NCT06863402 2025-12-23

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype